Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results

Abstract Background The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. Patients and methods Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50–100 μm Hepasphere/Quadrasphere Microsphere® particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre-and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated. Results A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients. Conclusions Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered.

[1]  D. Planchard,et al.  Interventional radiology: role in the treatment of liver metastases from GEP-NETs , 2015 .

[2]  M. Ducreux,et al.  Predisposing Factors of Liver Necrosis after Transcatheter Arterial Chemoembolization in Liver Metastases from Neuroendocrine Tumor , 2015, CardioVascular and Interventional Radiology.

[3]  D. Sze,et al.  The Efficacy of Hepatic 90Y Resin Radioembolization for Metastatic Neuroendocrine Tumors: A Meta-Analysis , 2014, The Journal of Nuclear Medicine.

[4]  M. Ozturk,et al.  Chemoembolization for neuroendocrine liver metastasis. , 2014, Hepato-gastroenterology.

[5]  F. Nevens,et al.  Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. , 2014, Journal of vascular and interventional radiology : JVIR.

[6]  P. Huppert,et al.  Transcatheter Arterial Chemoembolization (TACE) of Colorectal Cancer Liver Metastases by Irinotecan-Eluting Microspheres in a Salvage Patient Population , 2014, CardioVascular and Interventional Radiology.

[7]  Y. Bang,et al.  Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. , 2013, Journal of vascular and interventional radiology : JVIR.

[8]  T. Pawlik,et al.  Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury , 2013, CardioVascular and Interventional Radiology.

[9]  M. Bloomston,et al.  Extrahepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Neuroendocrine Carcinoma , 2013, Annals of Surgical Oncology.

[10]  A. Benson,et al.  Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. , 2012, International journal of radiation oncology, biology, physics.

[11]  T. de Baère,et al.  Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. , 2012, Journal of hepatology.

[12]  G. Benea,et al.  Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. , 2011, Anticancer research.

[13]  F. Nevens,et al.  A Randomized Phase II Study of Drug-Eluting Beads versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma , 2011, Oncology Research and Treatment.

[14]  M. Choti,et al.  Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis , 2011, Annals of Surgical Oncology.

[15]  C. Sadow,et al.  Hepatic Arterial Chemoembolization Using Drug-Eluting Beads in Gastrointestinal Neuroendocrine Tumor Metastatic to the Liver , 2011, CardioVascular and Interventional Radiology.

[16]  T. Vogl,et al.  Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. , 2010, AJR. American journal of roentgenology.

[17]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[18]  B. Sangro,et al.  Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. , 2008, Journal of vascular and interventional radiology : JVIR.

[19]  T. de Baère,et al.  Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. , 2008, Journal of vascular and interventional radiology : JVIR.

[20]  G. Benea,et al.  Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. , 2007, In vivo.

[21]  S. Stavropoulos,et al.  Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. , 2007, Journal of vascular and interventional radiology : JVIR.

[22]  T. Pilgram,et al.  Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. , 2007, AJR. American journal of roentgenology.

[23]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[24]  J. Bilbao,et al.  In Vivo Evaluation of a New Embolic Spherical Particle (HepaSphere) in a Kidney Animal Model , 2007, CardioVascular and Interventional Radiology.

[25]  K. Ahrar,et al.  Update on the management of neuroendocrine hepatic metastases. , 2006, Journal of vascular and interventional radiology : JVIR.

[26]  K. Ashizawa,et al.  Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. , 2003, AJR. American journal of roentgenology.

[27]  C. Loewe,et al.  Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. , 2003, AJR. American journal of roentgenology.

[28]  R. Corinaldesi,et al.  Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  D. Canes,et al.  Hepatic neuroendocrine metastases: does intervention alter outcomes? , 2000, Journal of the American College of Surgeons.